PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$111.46
as of September 28, 2026 -
YTD RETURNS9.59%
as of September 28, 2026 -
Total Net Assets$1.05B
as of September 28, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 2.45 | 8.50 | 11.15 | 29.87 | 13.65 | 10.41 | 8.78 | 10.31 |
| PPH (Market Price) | 2.43 | 8.57 | 11.13 | 29.92 | 13.65 | 10.41 | 8.79 | 10.39 |
| MVIS US Listed Pharmaceutical 25 Index | 2.46 | 8.50 | 10.94 | 29.69 | 13.30 | 10.05 | 8.53 | 10.12 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 09/28/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
20.79 |
216,423,763 |
|
MRK |
Merck & Co Inc |
13.38 |
139,210,269 |
|
NVO |
Novo Nordisk A/S |
5.61 |
58,407,545 |
|
PFE |
Pfizer Inc |
5.10 |
53,076,858 |
|
BMY |
Bristol-Myers Squibb Co |
4.89 |
50,917,151 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.58 |
47,662,759 |
|
GSK |
Gsk Plc |
4.54 |
47,222,405 |
|
MCK |
Mckesson Corp |
4.26 |
44,374,660 |
|
COR |
Cencora Inc |
4.17 |
43,417,183 |
|
HLN |
Haleon Plc |
3.69 |
38,409,911 |
|
NVS |
Novartis Ag |
3.65 |
37,955,848 |
|
ABBV |
Abbvie Inc |
3.62 |
37,702,851 |
|
AZN |
Astrazeneca Plc |
3.61 |
37,611,874 |
|
JNJ |
Johnson & Johnson |
3.48 |
36,174,517 |
|
SNY |
Sanofi Sa/France |
3.28 |
34,142,050 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.76 |
28,775,666 |
|
ZTS |
Zoetis Inc |
2.48 |
25,821,731 |
|
VTRS |
Viatris Inc |
1.52 |
15,801,778 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.33 |
13,874,330 |
|
CORT |
Corcept Therapeutics Inc |
0.76 |
7,889,897 |
|
AXSM |
Axsome Therapeutics Inc |
0.76 |
7,872,322 |
|
ELAN |
Elanco Animal Health Inc |
0.49 |
5,092,491 |
|
DFTX |
Definium Therapeutics Inc |
0.48 |
5,029,405 |
|
OGN |
Organon & Co |
0.28 |
2,954,669 |
|
PRGO |
Perrigo Co Plc |
0.11 |
1,113,776 |
|
-USD CASH- |
-- |
0.12 |
1,240,854 |
|
-- |
Other/Cash |
0.25 |
2,641,374 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 08/31/2026
-
Sector
% of Net Assets -
Health Care
99.79 -
Other/Cash
0.21
Country Weightings (%) as at 08/31/2026
-
Country
% of Net Assets -
United States
63.70 -
United Kingdom
10.90 -
Switzerland
9.98 -
Denmark
4.91 -
France
4.03 -
Israel
3.15 -
Japan
3.12 -
Other/Cash
0.21
Fees
Distributions
as of 09/28/2026
Quarterly
1.85%
2.24%
1.95%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency